NasdaqGM - Nasdaq Real Time Price USD

BioAtla, Inc. (BCAB)

2.3200 -0.0300 (-1.28%)
As of 10:37 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
250.0000
429.0000
Operating Expense
129,687.0000
129,687.0000
108,140.0000
96,690.0000
30,528.0000
Operating Income
-129,687.0000
-129,687.0000
-108,140.0000
-96,440.0000
-30,099.0000
Net Non Operating Interest Income Expense
6,312.0000
6,312.0000
1,648.0000
347.0000
-1,289.0000
Other Income Expense
-87.0000
-87.0000
10.0000
691.0000
-4,465.0000
Pretax Income
-123,462.0000
-123,462.0000
-106,482.0000
-95,402.0000
-35,853.0000
Net Income Common Stockholders
-123,462.0000
-123,462.0000
-106,482.0000
-95,402.0000
-35,853.0000
Diluted NI Available to Com Stockholders
-123,462.0000
-123,462.0000
-106,482.0000
-95,402.0000
-35,853.0000
Basic EPS
-2.58
--
-2.74
-2.76
-3.19
Diluted EPS
-2.58
--
-2.74
-2.76
-3.19
Basic Average Shares
47,777.5680
--
38,927.2680
34,561.2450
8,428.1530
Diluted Average Shares
47,777.5680
--
38,927.2680
34,561.2450
8,428.1530
Total Operating Income as Reported
-129,687.0000
-129,687.0000
-108,140.0000
-96,440.0000
-30,099.0000
Total Expenses
129,687.0000
129,687.0000
108,140.0000
96,690.0000
30,528.0000
Net Income from Continuing & Discontinued Operation
-123,462.0000
-123,462.0000
-106,482.0000
-95,402.0000
-35,853.0000
Normalized Income
-123,462.0000
-123,462.0000
-106,482.0000
-96,092.0000
-31,389.0000
Interest Income
6,312.0000
6,312.0000
1,648.0000
350.0000
100.0000
Interest Expense
--
--
--
3.0000
1,389.0000
Net Interest Income
6,312.0000
6,312.0000
1,648.0000
347.0000
-1,289.0000
EBIT
-129,687.0000
-129,687.0000
-108,140.0000
-95,399.0000
-34,464.0000
EBITDA
-128,466.0000
-128,466.0000
-106,941.0000
-94,069.0000
-33,456.0000
Reconciled Depreciation
1,221.0000
1,221.0000
1,199.0000
1,330.0000
1,008.0000
Net Income from Continuing Operation Net Minority Interest
-123,462.0000
-123,462.0000
-106,482.0000
-95,402.0000
-35,853.0000
Total Unusual Items Excluding Goodwill
--
--
--
690.0000
-4,464.0000
Total Unusual Items
--
--
--
690.0000
-4,464.0000
Normalized EBITDA
-128,466.0000
-128,466.0000
-106,941.0000
-94,759.0000
-28,992.0000
12/31/2020 - 12/16/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ACHL Achilles Therapeutics plc
0.7780
-1.46%
 
STRO Sutro Biopharma, Inc.
3.3250
-4.17%
 
NUVB Nuvation Bio Inc.
2.6100
-1.88%
 
CGEM Cullinan Therapeutics, Inc.
18.95
+0.32%
 
BOLT Bolt Biotherapeutics, Inc.
1.1800
-0.85%
 
VOR Vor Biopharma Inc.
1.6750
-3.74%
 
ITOS iTeos Therapeutics, Inc.
10.39
-1.70%
 
VINC Vincerx Pharma, Inc.
0.9179
-1.30%
 
IKNA Ikena Oncology, Inc.
1.3100
+1.55%
 
XLO Xilio Therapeutics, Inc.
1.0300
-2.86%